Skip to main content
. Author manuscript; available in PMC: 2011 Jun 24.
Published in final edited form as: Biol Psychiatry. 2010 Jun 19;68(6):553–559. doi: 10.1016/j.biopsych.2010.04.025

Table 1.

Demographic and clinical characteristics of patients with relapsing-remitting multiple sclerosis (RRMS) and healthy control subjects.

Healthy controls RRMS p
n 20 29
Age 35.1±1.9 37.5±1.6 .33
Male/Female 2 / 18 4 / 25 .69
Brain atrophy (BPF) 0.84±0.004 0.82±0.005 .006
Lesion volume [cm3] N/A 7.1±2.0
EDSS N/A 2.5±0.2
Disease duration N/A 6.7±1.0
DMT (None, IFNβ, GA, Nat) N/A 7 / 13 / 8 / 1
BDI-II 1.6±0.5 9.5±1.6 <.001
BAI 2.1±0.6 8.3±1.4 .001
SSRI treatment 0 6

BPF=Brain Parenchymal Fraction; EDSS=Expanded Disability Status Scale, DMT=disease-modifying therapy; IFNβ=Interferon-β GA=Glatiramer Acetate; Nat=Natalizumab; BDI=Beck Depression Inventory, BAI=Beck Anxiety Inventory; SSRI=Selective serotonin reuptake inhibitor